Successful chemotherapy with a docetaxel regimen for primary signet-ring cell carcinoma of the urinary bladder - A case report

Keita Tagami, Shigeru Tanda, Yohei Satake, Akira Takeuchi, Yuko Abe, Takashige Namima, Hiroaki Kusunose, Mitsuhisa Muto, Hiroshi Nagura

Research output: Contribution to journalArticlepeer-review

Abstract

Primary signet-ring cell carcinoma of the bladder is rare and has a poor prognosis. In addition, there are few successful chemotherapies for it. We report a case of chemotherapy with a docetaxel regimen which was efficacious in a 64-year-old Japanese man suffering from the disease. The onset of bilateral hydronephrosis led to the detection of his bladder tumor, and its pathological diagnosis was signet-ring cell carcinoma (immunohistochemistry showed cytokeratin 7+/20±). He was treated with chemotherapy rather than with surgery because the tumor invaded the abdominal wall and groin. To treat his disease, we performed 2 courses of a chemotherapy regimen comprised of S-1 and cisplatin, but it was not efficacious. We chose docetaxel as a second-line chemotherapy regimen, (60 mg/m2, tri-weekly), and a clinical examination including contrast-enhanced CT showed that his disease had successfully responded to the chemotherapy.

Original languageEnglish
Pages (from-to)1737-1741
Number of pages5
JournalJapanese Journal of Cancer and Chemotherapy
Volume39
Issue number11
Publication statusPublished - 2012 Nov
Externally publishedYes

Keywords

  • Chemotherapy
  • Docetaxel
  • Primary signet-ring cell carcinoma of the urinary bladder

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Successful chemotherapy with a docetaxel regimen for primary signet-ring cell carcinoma of the urinary bladder - A case report'. Together they form a unique fingerprint.

Cite this